欢迎来到天天文库
浏览记录
ID:38186480
大小:216.06 KB
页数:3页
时间:2019-05-22
《奥曲肽持续皮下泵入治疗恶性肠梗阻的临床观察》由会员上传分享,免费在线阅读,更多相关内容在行业资料-天天文库。
1、·450·临床肿瘤学杂志2010年5月第15卷第5期ChineseClinicalOneolo~,May.2010,Vo1.15,No.5奥曲肽持续皮下泵入治疗恶性肠梗阻的临床观察110032沈阳辽宁中医药大学附属医院肿瘤科邢玉庆,殷东风,高宏,潘玉真,朱颖,潘琳,邢向荣【摘要】目的观察奥曲肽持续皮下泵入给药在恶性肠梗阻姑息性治疗中的作用。方法收集2007年3月至2009年4月收治的26例恶性肠梗阻患者进行回顾分析。分为奥曲肽组11例和对照组15例,比较两组患者在治疗前后肠梗阻相关症状变化、肛门恢复排气排便时间、胃肠减压引流液量、鼻胃管留置时间、拔管率和肠梗阻近期疗效。结果奥曲
2、肽组肠梗阻相关症状改善率为81.8%(9/11),明显优于对照组46.7%(7/15)。奥曲肽组患者恢复排气排便所需平均时间为3.2天,明显优于对照组5.8天。奥曲肽组鼻胃管留置时间为(5±1.2)天,拔管率为54.5%,均明显优于对照组(10±2.3)天和20.0%。奥曲肽组肠梗阻的近期疗效好转率为72.7%,优于对照组26.7%。结论奥曲肽持续皮下泵入给药配合常规治疗,能够显著改善晚期恶性肠梗阻患者,尤其是终末期患者的生活质量,为恶性肠梗阻的治疗提供了一种新的治疗思路和方法。【关键词】恶性肠梗阻;奥曲肽;持续皮下泵入;姑息治疗中图分类号:R730.5文献标识码:A文章编号:
3、1009—0460(2010)05—0450—03Clinicalobservationofcontinuouslysubcutaneous-pumpedoctreotideinfusioninpalliativetreatmentofma-lignantbowelobstructionXINGYu—qing。YINDong-feng,GAOHong,PANYu-zhen,ZHUYing,PANLin,XINGXiang。rong.Depart‘mentofInternalOneology,AffiliatedHospitalofLiaoningUniversityofTrad
4、itionalChineseMedicine,Shenyang110032,ChinaCorrespondingauthor:YINDong-feng,E—mail:lnzy—oncology@yahoo.com.cn【Abstract】ObjectiveToinvestigatetheeffectivenessofcontinuouslysubcutaneous—pumpedoctreotideinfusioninpalliativetreatmentofmalignantbowelobstruction(MBO)duetoadvancedcarcinomapatients.
5、MethodsClinicaldatawereretrospectivelyal—alyzedin26carcinomapatientscomplicatedwithmalignantbowelobstruction,inhospit~affiliatedtoliaoninguniversityoftraditionalchinesemedicinefromMarch2007toApril2009.Twenty—sixcarcinomapatientswithMBOweredividedintotwogroups:controlgroup(routinetherapy,15pa
6、tients)andstilamingroup(11patients).Stilamingroup(SG)receivedroutinetherapycombinedwithstilamin(0.3mg/d)by24hourscontinuoussubcutaneousstilamininfusion.Thecurativeeffectivenessrelatedsymptomchange,thetimethattheanusrestorestheexhaustbowelmovementisrequireliquidvolumestomachandintestinesreduc
7、edpressuredrainaged,nasal—store—achtubeleavingtimeandextubationratewereobservedandcomparedbetweenthetwogroups.ResultsAftertreatment,remarkablechangingrateofMBOrelatedsymptomwas81.8%(9/11)inSG,46.7%(7/15)inCG(controlgruop)(P<0.05).78%ofSGand30%0fCGr
此文档下载收益归作者所有